DK1379254T3 - Anvendelse af galdesyre- eller galdesalt-fedtsyre-konjugater - Google Patents

Anvendelse af galdesyre- eller galdesalt-fedtsyre-konjugater

Info

Publication number
DK1379254T3
DK1379254T3 DK02761957T DK02761957T DK1379254T3 DK 1379254 T3 DK1379254 T3 DK 1379254T3 DK 02761957 T DK02761957 T DK 02761957T DK 02761957 T DK02761957 T DK 02761957T DK 1379254 T3 DK1379254 T3 DK 1379254T3
Authority
DK
Denmark
Prior art keywords
bile
acid
fatty acid
bile salt
stands
Prior art date
Application number
DK02761957T
Other languages
Danish (da)
English (en)
Inventor
Tuvia Gilat
Original Assignee
Galmed Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Int Ltd filed Critical Galmed Int Ltd
Application granted granted Critical
Publication of DK1379254T3 publication Critical patent/DK1379254T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02761957T 2001-04-17 2002-04-15 Anvendelse af galdesyre- eller galdesalt-fedtsyre-konjugater DK1379254T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (1)

Publication Number Publication Date
DK1379254T3 true DK1379254T3 (da) 2007-10-15

Family

ID=11075322

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02761957T DK1379254T3 (da) 2001-04-17 2002-04-15 Anvendelse af galdesyre- eller galdesalt-fedtsyre-konjugater
DK07002485T DK1790346T3 (da) 2001-04-17 2002-04-15 Anvendelse af galdesyre eller galdesalt-fedtsyre-konjugater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07002485T DK1790346T3 (da) 2001-04-17 2002-04-15 Anvendelse af galdesyre eller galdesalt-fedtsyre-konjugater

Country Status (24)

Country Link
US (2) US7501403B2 (cs)
EP (2) EP1790346B1 (cs)
JP (1) JP4324706B2 (cs)
KR (1) KR100883080B1 (cs)
CN (1) CN1259918C (cs)
AT (2) ATE432705T1 (cs)
AU (2) AU2002307771B2 (cs)
BR (1) BR0208924A (cs)
CA (2) CA2444266C (cs)
CY (1) CY1106853T1 (cs)
CZ (2) CZ309042B6 (cs)
DE (2) DE60232559D1 (cs)
DK (2) DK1379254T3 (cs)
EA (1) EA007565B1 (cs)
ES (2) ES2289137T3 (cs)
HU (1) HU230548B1 (cs)
IL (1) IL142650A (cs)
MX (1) MXPA03009553A (cs)
NO (2) NO333910B1 (cs)
NZ (1) NZ528868A (cs)
PL (2) PL205057B1 (cs)
PT (2) PT1379254E (cs)
UA (1) UA78699C2 (cs)
WO (1) WO2002083147A1 (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
KR20110120866A (ko) * 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
US9084826B2 (en) 2012-05-01 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists; compositions and method of uses
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
KR101702251B1 (ko) * 2012-11-29 2017-02-02 에스티팜 주식회사 신규한 소포 수송에 이용하기 위한 담즙산 올리고머 결합체 및 이의 용도
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
HUE045209T2 (hu) * 2013-12-04 2019-12-30 Galmed Res & Development Ltd Aramchol-sók
WO2016199137A1 (en) * 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
WO2015186126A1 (en) * 2014-06-01 2015-12-10 Galmed Research And Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤

Also Published As

Publication number Publication date
CA2703688A1 (en) 2002-10-24
EP1379254B1 (en) 2007-06-20
CA2444266C (en) 2010-07-27
CZ300489B6 (cs) 2009-06-03
AU2002307771B2 (en) 2006-10-19
ES2328966T3 (es) 2009-11-19
NZ528868A (en) 2005-09-30
EA200301017A1 (ru) 2005-04-28
KR20030092063A (ko) 2003-12-03
CZ2008296A3 (cs) 2004-04-14
CA2444266A1 (en) 2002-10-24
ES2289137T3 (es) 2008-02-01
US20040121993A1 (en) 2004-06-24
WO2002083147A1 (en) 2002-10-24
KR100883080B1 (ko) 2009-02-10
JP2004525962A (ja) 2004-08-26
PL211438B1 (pl) 2012-05-31
DE60220775T2 (de) 2008-03-06
CY1106853T1 (el) 2012-05-23
CA2703688C (en) 2012-07-31
EP1790346A3 (en) 2007-08-22
PL366585A1 (en) 2005-02-07
EP1790346B1 (en) 2009-06-03
NO333910B1 (no) 2013-10-14
EA007565B1 (ru) 2006-12-29
UA78699C2 (en) 2007-04-25
CZ309042B6 (cs) 2021-12-22
HUP0400801A2 (hu) 2004-08-30
HU230548B1 (hu) 2016-11-28
NO20034609L (no) 2003-11-28
JP4324706B2 (ja) 2009-09-02
DE60232559D1 (de) 2009-07-16
CZ20032710A3 (cs) 2004-04-14
US8110564B2 (en) 2012-02-07
IL142650A (en) 2007-06-03
HUP0400801A3 (en) 2012-09-28
AU2007200191B2 (en) 2008-09-04
US7501403B2 (en) 2009-03-10
NO335087B1 (no) 2014-09-08
AU2007200191A1 (en) 2007-02-08
DK1790346T3 (da) 2009-10-12
MXPA03009553A (es) 2004-05-24
CN1529603A (zh) 2004-09-15
PL205057B1 (pl) 2010-03-31
NO20131219L (no) 2003-11-28
CN1259918C (zh) 2006-06-21
PT1379254E (pt) 2007-07-10
EP1379254A1 (en) 2004-01-14
EP1790346A2 (en) 2007-05-30
IL142650A0 (en) 2002-03-10
ATE432705T1 (de) 2009-06-15
DE60220775D1 (de) 2007-08-02
PT1790346E (pt) 2009-09-04
US20090149537A1 (en) 2009-06-11
ATE365044T1 (de) 2007-07-15
NO20034609D0 (no) 2003-10-15
BR0208924A (pt) 2004-04-20

Similar Documents

Publication Publication Date Title
DK1379254T3 (da) Anvendelse af galdesyre- eller galdesalt-fedtsyre-konjugater
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
EP1196444B8 (en) Exendin-4 conjugates and their medical use
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
EP2845596A3 (en) Use of lipid conjugates in the treatment of disease
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
DE60232434D1 (de) Neue interferon-beta-ähnliche moleküle
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
WO2003051389A3 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
JP2004525962A5 (cs)
IS6879A (is) Neublastín sem tengt er fjölliðu og aðferðir við notkun þess
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
ID25478A (id) Agonis 5-ht1f
WO2002038566A3 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
EP2266558A3 (en) Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists
WO2000035432A3 (en) Improved viscoelastic compositions and methods of use
AU2002328253A1 (en) Pna conjugate for the treatment of diseases associated with hiv
HK1064941A (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases